Ci Pan1,2, Jiao-Yang Cai1,2, Min Xu1,3, Qi-Dong Ye1,2, Min Zhou1,2, Min-Zhi Yin1,4, Yu-Min Zhong1,5, Jing Chen1,2, Shu-Hong Shen1,2, Jing-Yan Tang6,7. 1. , Shanghai, China. 2. Department of Hematology/Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University, School of Medicine, Shanghai, China. 3. Department of Surgery, Shanghai Children's Medical Center, Shanghai Jiao Tong University, School of Medicine, Shanghai, China. 4. Department of Pathology, Shanghai Children's Medical Center, Shanghai Jiao Tong University, School of Medicine, Shanghai, China. 5. Department of Radiology, Shanghai Children's Medical Center, Shanghai Jiao Tong University, School of Medicine, Shanghai, China. 6. , Shanghai, China. tangjingyan@scmc.com.cn. 7. Department of Hematology/Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University, School of Medicine, Shanghai, China. tangjingyan@scmc.com.cn.
Abstract
BACKGROUND: The clinical management of children with renal tumors including Wilms' tumor, clear cell sarcoma, rhabdoid tumor and other renal tumors in our center was designed according to the National Wilms' Tumor Study Group protocols. METHODS: A total of 142 consecutive patients who had been diagnosed as having renal tumors at Shanghai Children's Medical Center were reviewed retrospectively in the period of December 1998 and September 2012. Diagnosis and treatment were decided by a multidisciplinary team including oncologists, surgeons, pathologists and sub-specialized radiologists. RESULTS: The median age of the patients at the time of diagnosis was 27 months. The tumor stages of the patients were as follows: stage I 24.6%, stage II 23.2%, stage III 32.3%, stage IV 14.1%, and stage V 5.6%. Favorable histology was diagnosed in 80.3%, anaplasia in 4.2%, clear cell sarcoma in 9.8%, rhabdoid tumor in 4.9%, and other renal tumors in 0.7% of the patients. The event-free and overall 5-year survival rates were 80% and 83%, respectively. Tumor relapse and progress was seen in 25 patients (17.6%). The median relapse time was 6 months (range: 2-37 months). Seven relapsing patients were retreated and four of them got second complete remission (three in stage II, one in stage I). CONCLUSION: A multi-disciplinary team work model is feasible in developing countries, and the renal tumors protocols basically from developed countries are safe in developing countries.
BACKGROUND: The clinical management of children with renal tumors including Wilms' tumor, clear cell sarcoma, rhabdoid tumor and other renal tumors in our center was designed according to the National Wilms' Tumor Study Group protocols. METHODS: A total of 142 consecutive patients who had been diagnosed as having renal tumors at Shanghai Children's Medical Center were reviewed retrospectively in the period of December 1998 and September 2012. Diagnosis and treatment were decided by a multidisciplinary team including oncologists, surgeons, pathologists and sub-specialized radiologists. RESULTS: The median age of the patients at the time of diagnosis was 27 months. The tumor stages of the patients were as follows: stage I 24.6%, stage II 23.2%, stage III 32.3%, stage IV 14.1%, and stage V 5.6%. Favorable histology was diagnosed in 80.3%, anaplasia in 4.2%, clear cell sarcoma in 9.8%, rhabdoid tumor in 4.9%, and other renal tumors in 0.7% of the patients. The event-free and overall 5-year survival rates were 80% and 83%, respectively. Tumor relapse and progress was seen in 25 patients (17.6%). The median relapse time was 6 months (range: 2-37 months). Seven relapsing patients were retreated and four of them got second complete remission (three in stage II, one in stage I). CONCLUSION: A multi-disciplinary team work model is feasible in developing countries, and the renal tumors protocols basically from developed countries are safe in developing countries.
Authors: John A Kalapurakal; Jeffrey S Dome; Elizabeth J Perlman; Marcio Malogolowkin; Gerald M Haase; Paul Grundy; Max J Coppes Journal: Lancet Oncol Date: 2004-01 Impact factor: 41.316
Authors: D M Green; N E Breslow; J B Beckwith; J Z Finklestein; P Grundy; P R Thomas; T Kim; S Shochat; G Haase; M Ritchey; P Kelalis; G J D'Angio Journal: J Clin Oncol Date: 1998-12 Impact factor: 44.544
Authors: Yevgeny Grigoriev; Jane Lange; Susan M Peterson; Janice R Takashima; Michael L Ritchey; Dicken Ko; James H Feusner; Robert C Shamberger; Daniel M Green; Norman E Breslow Journal: Pediatr Nephrol Date: 2012-03-20 Impact factor: 3.714
Authors: Robert C Shamberger; James R Anderson; Norman E Breslow; Elizabeth J Perlman; J Bruce Beckwith; Michael L Ritchey; Gerald M Haase; Milton Donaldson; Paul E Grundy; Robert Weetman; Max J Coppes; Marcio Malogolowkin; Patricia D Shearer; Morris Kletzel; Patrick R M Thomas; Roger Macklis; Vicki Huff; Douglas A Weeks; Daniel M Green Journal: Ann Surg Date: 2010-03 Impact factor: 12.969
Authors: A M Abu-Ghosh; M D Krailo; S C Goldman; R S Slack; V Davenport; E Morris; J H Laver; G H Reaman; M S Cairo Journal: Ann Oncol Date: 2002-03 Impact factor: 32.976
Authors: Malcolm A Smith; Nita L Seibel; Sean F Altekruse; Lynn A G Ries; Danielle L Melbert; Maura O'Leary; Franklin O Smith; Gregory H Reaman Journal: J Clin Oncol Date: 2010-04-19 Impact factor: 44.544
Authors: Jeffrey S Dome; Cecilia A Cotton; Elizabeth J Perlman; Norman E Breslow; John A Kalapurakal; Michael L Ritchey; Paul E Grundy; Marcio Malogolowkin; J Bruce Beckwith; Robert C Shamberger; Gerald M Haase; Max J Coppes; Peter Coccia; Morris Kletzel; Robert M Weetman; Milton Donaldson; Roger M Macklis; Daniel M Green Journal: J Clin Oncol Date: 2006-05-20 Impact factor: 44.544
Authors: G J D'Angio; N Breslow; J B Beckwith; A Evans; H Baum; A deLorimier; D Fernbach; E Hrabovsky; B Jones; P Kelalis Journal: Cancer Date: 1989-07-15 Impact factor: 6.860
Authors: Marcio Malogolowkin; Cecilia A Cotton; Daniel M Green; Norman E Breslow; Elizabeth Perlman; James Miser; Michael L Ritchey; Patrick R M Thomas; Paul E Grundy; Giulio J D'Angio; J Bruce Beckwith; Robert C Shamberger; Gerald M Haase; Milton Donaldson; Robert Weetman; Max J Coppes; Patricia Shearer; Peter Coccia; Morris Kletzel; Roger Macklis; Gail Tomlinson; Vicki Huff; Robert Newbury; Douglas Weeks Journal: Pediatr Blood Cancer Date: 2008-02 Impact factor: 3.167